Abstract Beta-2-Glycoprotein I (β2GPI) plays a number of essential roles throughout the
body. β2GPI, C-reactive protein and thrombomodulin are the only three proteins that …

Diagnosis of antiphospholipid syndrome (APS) requires the presence of a clinical criterion
(thrombosis and/or pregnancy morbidity), combined with persistently circulating …

Background Critically ill patients with coronavirus disease 2019 (COVID-19) have a
profound hypercoagulable state and often develop coagulopathy which leads to organ …

Antiphospholipid syndrome, also known as 'Hughes Syndrome', is an autoimmune disease
characterised by a set of clinical manifestations, almost all of which are direct or indirect …

Recurrent thrombosis and miscarriages are the main clinical manifestations of
antiphospholipid syndrome (APS). Although most patients display both clinical signs, some …

Background Despite expansion in the 2006 Sydney antiphospholipid syndrome (APS)
classification criteria to include IgG/IgM anti-β2-glycoprotein (aβ2GPI) antibodies in addition …

Antiphospholipid antibodies (aPL) are mandatory for the diagnosis but are also a risk factor
for the antiphospholipid syndrome (APS) clinical manifestations. Lupus anticoagulant (LA) …

The present clinical and laboratory classification criteria for antiphospholipid syndrome
(APS) were established in Sydney, Australia, in 2006. In this review, we focus on the …

Anti-phospholipid syndrome (APS) is an acquired pro-thrombotic autoimmune disease that
predisposes to thrombotic events and/or obstetric complications, in the persistent presence …

The diagnosis of antiphospholipid syndrome (APS) relies on the detection of
antiphospholipid antibodies (aPL). Currently, lupus anticoagulant (LA), anticardiolipin (aCL) …